Drug Trial Radar · NCT02860624
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Last checked: Nov 19, 2026Latest source record: Aug 9, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
550
Actual
Start
Dec 2011
Primary completion
Apr 2013
Sponsor
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
Conditions
- Gastroesophageal Reflux Disease
Interventions
10 mg ilaprazoleDrug
Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
40mg esomeprazoleDrug
One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in stage of the ulcer assessed by endoscopic(week 8) changes relative to baseline (week 0) levels.Time frame: week 8
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.